Holding:
In Tris Pharma Inc. v. Actavis Laboratories FL, Inc.,
No. 21-1495 (Fed. Cir. July 7, 2022) (non-precedential), the Court
of Appeals for the Federal Circuit ("Federal Circuit")
affirmed the district court's holding that Actavis failed to
show that the challenged claims would have been obvious.
Background:
Tris Pharma, Inc. ("Tris") owns U.S. Patent Nos.
8,465,765 ("the '765 patent"), 8,563,033 ("the
'033 patent"), and 8,778,390 ("the '390
patent"), which have claims related to a liquid
methylphenidate ("MPH") oral suspension with certain
pharmacodynamic and pharmacokinetic properties. MPH is used to
treat attention deficit hyperactivity disorder.
Tris asserted claims of all three patents against Actavis
Laboratories FL, Inc. ("Actavis") in the U.S. District
Court for the District of Delaware. The district court judge held
that all asserted claims would have been obvious under 35 U.S.C.
§ 103. Tris Pharma, Inc. v. Actavis Lab'ys FL,
Inc., 276 F.